In a phase 1b/2a randomized, double-blind, placebo-controlled study, the weekly administration of HM15211 (efocipegtrutide), a GLP-1/GCG/GIP triple incretin agonist, was assessed in 66 non-T2DM patients with biopsy-proven MASH [109]. This evidence concerns the gene GCG and type 2 diabetes mellitus.